Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | FGFR2 |
Variant | over exp |
Impact List | none |
Protein Effect | no effect |
Gene Variant Descriptions | FGFR2 over exp indicates an over expression of the Fgfr2 protein and/or mRNA. However, the mechanism causing the over expression is unspecified. |
Associated Drug Resistance | |
Category Variants Paths |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS | 17 |
NCT05111626 | Phase I | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Bemarituzumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 16 |
NCT05322577 | Phase I | Bemarituzumab + Nivolumab + Oxaliplatin + Tegafur-gimeracil-oteracil Potassium Bemarituzumab + Capecitabine + Oxaliplatin Bemarituzumab + Capecitabine + Nivolumab + Oxaliplatin | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (FORTITUDE-103) | Recruiting | USA | 4 |
NCT03694522 | Phase II | Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin | A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 10 |
NCT05052801 | Phase III | Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101) | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | AUS | 28 |
NCT05859477 | Phase II | Capecitabine + Nivolumab + Oxaliplatin | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer (NIVOFGFR2) | Recruiting | USA | 0 |
NCT03517956 | Phase I | Copanlisib + Rogaratinib | Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO) | Completed | USA | ESP | DEU | BEL | 2 |
NCT03088059 | Phase II | Niraparib Durvalumab + Monalizumab Methotrexate Carboplatin Rogaratinib Mitomycin C Docetaxel Afatinib Paclitaxel Durvalumab Monalizumab Palbociclib Bleomycin Gemcitabine Fluorouracil | Biomarker-based Study in R/M SCCHN (UPSTREAM) | Active, not recruiting | ITA | GBR | FRA | ESP | BEL | 0 |